{"id":"NCT03399604","sponsor":"Liquidia Technologies, Inc.","briefTitle":"Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil","officialTitle":"A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-01-02","primaryCompletion":"2019-05-06","completion":"2019-11-25","firstPosted":"2018-01-16","resultsPosted":"2024-07-30","lastUpdate":"2024-07-30"},"enrollment":121,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Pulmonary Hypertension"],"interventions":[{"type":"DRUG","name":"LIQ861 Inhaled Treprostinil","otherNames":["inhaled treprostinil","inhaled prostacyclin"]}],"arms":[{"label":"LIQ861 Inhaled Treprostinil","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the long-term safety and tolerability of LIQ861, a dry powder formulation of treprostinil, in patients with Pulmonary Arterial Hypertension (PAH).","primaryOutcome":{"measure":"Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events","timeFrame":"Baseline, Week 2, Month 1, Month 2 Visits, with bimonthly follow up for up to 16 months.","effectByArm":[{"arm":"LIQ861 Inhaled Treprostinil","deltaMin":121,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":21},"locations":{"siteCount":38,"countries":["United States"]},"refs":{"pmids":["33282202"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":121},"commonTop":["Cough","Headache","Upper Respiratory Tract Infection","Dysponea","Dizziness"]}}